2Flo Ventures

2Flo Ventures investment thesis

Vivacelle Bio Vivacelle Bio leverages phospholipid nanoparticles treating relative (nitric oxide induced) and absolute hypovolemia due to septic or hemorrhagic shock. Temprian Therapeutics A biotech company focused on developing a safe and effective treatment for the skin depigmentation disease, Vitiligo. Delphian Therapeutics Delphian Therapeutics is a pioneer in FDA-approved, cannabinoid-based pain relief for hard-to-treat musculoskeletal and neurological conditions. Pain is commonly undertreated in patients of color and is shown to exacerbate adverse health outcomes. ResQ Pharma ResQ Pharma is a life sciences company seeking to reduce disparities in overdose deaths by improving access to easy-to-use antidotes for non-opiate drug overdoses. KeyCare KeyCare, the only virtual care platform

2Flo Ventures team (5)

Partners and principals at 2Flo Ventures:

• Lyle Berkowitz — sweet spot $1.5M
• Paul Burton — sweet spot $1.5M
• John Cunningham — sweet spot $1.5M
• Elsie Oyoo — sweet spot $1.5M
• Sharon Ray — sweet spot $1.5M

2Flo Ventures portfolio companies

Companies listed on 2Flo Ventures's public materials include: Skip to main content, Portfolio, Team, News, Events, Pitch to Us, Quick Links, admin@2FloVentures.com, LinkedIn, Vivacelle Bio, Temprian Therapeutics, Delphian Therapeutics, ResQ Pharma, KeyCare, CancerIQ, Temprian Oncology, Akan Biosciences, 4D Healthware, Have a Healthcare Innovation?.

Is 2Flo Ventures a fit for your round?

Upload your pitch deck and see whether anyone at 2Flo Ventures appears in your top matches.